Business Context and Reporting Period
Corbus Pharmaceuticals Holdings, Inc. filed this Form 8-K on January 26, 2018, reporting the entry into a Material Definitive Agreement with the Cystic Fibrosis Foundation (CFF). The Company is an emerging growth company focused on developing lenabasum (formerly anabasum) for the treatment of cystic fibrosis (CF) and other fibrotic diseases.
Key Financial Metrics and Obligations
- Funding Award: Up to $25 million in total funding to support a Phase 2b Clinical Trial.
- Immediate Cash Inflow: $2,500,000 received upon execution of the agreement.
- Future Payments: Remaining funds paid incrementally based on clinical trial milestones.
- Approval Royalties: Obligation to pay 1.5x the Award amount ($37.5 million) upon first US approval and another 1.5x upon approval in another major market. The first royalty may be paid in cash or Company common stock.
- Sales Royalties: 2.5% of net sales for CF and related indications; 1% for non-field products.
- Transaction Royalties: 10% of proceeds from license or sale of lenabasum for CF, capped at 5x the Award amount.
- Equity Issuance: Issued a warrant to CFF for 1,000,000 shares of Common Stock at an exercise price of $13.20 per share (500,000 immediately exercisable).
Material Changes and Clinical Progress
The filing details a significant strategic partnership and regulatory milestone:
- Agreement Execution: Formalized the Cystic Fibrosis Program Related Investment Agreement with CFF.
- FDA Agreement: On January 29, 2018, the Company announced agreement with the FDA on the Phase 2b trial design. The FDA accepted the event rate of pulmonary exacerbation as the primary efficacy endpoint.
- Trial Scope: The study will enroll approximately 415 subjects (adults and adolescents 12-17) across ~100 sites globally. It is a double-blinded, randomized, placebo-controlled study testing two dosing regimens of lenabasum over 28 weeks.
Outlook, Risks, and Contingencies
- Termination Risks: The agreement may be terminated for cause if the Company materially fails to achieve commercialization or development milestones. Payment obligations survive termination.
- Indemnification: The Company must indemnify CFF against claims arising from the clinical trial, breaches of representations, or IP infringement.
- Equity Dilution: Potential dilution from the CFF Warrant and the option to pay approval royalties in common stock.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks related to clinical timelines, regulatory approval, and market competition.
Investor Verification Checklist
- Verify the specific milestones required to unlock the remaining $22.5 million of the funding award.
- Review the full text of the Agreement and CFF Warrant (filed as exhibits to the 10-K) for omitted terms under Confidential Treatment Requests.
- Monitor the enrollment progress and primary endpoint results of the Phase 2b Clinical Trial.
- Assess the potential dilution impact of the 1,000,000 share warrant and potential stock issuance for royalty payments.
- Confirm the Company's cash runway relative to the $2.5 million immediate receipt and ongoing burn rate.